A Multi-center, Open-label Long-Term Study of TS-142 in Patients With Insomnia Disorder
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Vornorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational
- Sponsors Taisho Pharmaceutical
Most Recent Events
- 17 Mar 2024 Status changed from active, no longer recruiting to completed.
- 18 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Oct 2022 Status changed from not yet recruiting to recruiting.